Ribozyme targeting of HIV-1 LTR
- PMID: 8093072
- DOI: 10.1006/bbrc.1994.2266
Ribozyme targeting of HIV-1 LTR
Abstract
The 5'-TAR region of HIV-1 mRNA is highly conserved amongst different HIV-1 isolates. We thus investigated the potential for in vivo targeting of the TAR RNA element by a hammerhead ribozyme. The use of the CAT reporter gene linked to the HIV1-LTR, in transient assays, reveals that a hammerhead ribozyme directed towards the first GUC of HIV-1 mRNA can efficiently inhibit CAT protein expression. We show that this inhibition is sequence-specific and probably due to a cleavage activity rather than an antisense effect. We show also that a hammerhead ribozyme that is inactive in vitro is capable of inhibiting CAT protein expression in a cellular environment. These results suggest that the targeting of the HIV-1 LTR by a hammerhead ribozyme constitutes a viable approach for anti-HIV therapy.
Similar articles
-
High expression of exogenous cDNAs directed by HIV-1 long terminal repeat in human cells constitutively producing HIV-1 tat and adenovirus E1A/E1B.Biotechniques. 1991 Mar;10(3):344-53. Biotechniques. 1991. PMID: 1829615
-
Evaluation of relative promoter strengths of the HIV-1-LTR and a chimeric RSV-LTR in T lymphocytic cells and peripheral blood mononuclear cells: promoters for anti-HIV-1 gene therapies.Gene Ther. 1996 Aug;3(8):725-30. Gene Ther. 1996. PMID: 8854098
-
HIV-1 TAR as anchoring site for optimized catalytic RNAs.Biol Chem. 2003 Mar;384(3):343-50. doi: 10.1515/BC.2003.040. Biol Chem. 2003. PMID: 12715885
-
The human immunodeficiency virus type-1 long terminal repeat and its role in gene expression.Prog Nucleic Acid Res Mol Biol. 1994;49:157-96. doi: 10.1016/s0079-6603(08)60050-1. Prog Nucleic Acid Res Mol Biol. 1994. PMID: 7863006 Review. No abstract available.
-
Ribozyme mimics as catalytic antisense reagents.Appl Biochem Biotechnol. 1995 Jul-Sep;54(1-3):43-56. doi: 10.1007/BF02787910. Appl Biochem Biotechnol. 1995. PMID: 7486984 Review.
Cited by
-
Trafficking through the Rev/RRE pathway is essential for efficient inhibition of human immunodeficiency virus type 1 by an antisense RNA derived from the envelope gene.J Virol. 2009 Jan;83(2):940-52. doi: 10.1128/JVI.01520-08. Epub 2008 Oct 29. J Virol. 2009. PMID: 18971264 Free PMC article.
-
Gene therapy. Clinical potential and relationship to drug treatment.Drugs. 1995 Dec;50(6):951-8. doi: 10.2165/00003495-199550060-00003. Drugs. 1995. PMID: 8612473 Review. No abstract available.
-
Nuclear Factor 90(NF90) targeted to TAR RNA inhibits transcriptional activation of HIV-1.Retrovirology. 2007 Jun 12;4:41. doi: 10.1186/1742-4690-4-41. Retrovirology. 2007. PMID: 17565699 Free PMC article.
-
Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint.Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):754-8. doi: 10.1073/pnas.93.2.754. Proc Natl Acad Sci U S A. 1996. PMID: 8570629 Free PMC article.
-
HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture.Nucleic Acids Res. 2000 Nov 1;28(21):4059-67. doi: 10.1093/nar/28.21.4059. Nucleic Acids Res. 2000. PMID: 11058100 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous